Skip to content
Clinical Trials – home

Allergenic Extract of Olea Europaea Pollen Polymerized with Glutaraldehyde: A Promising Treatment for Olive Pollen Allergy

1 / 3
trials open to patients / all trials
1+
Countries

In short

Recent clinical trials are investigating the use of Allergenic Extract of Olea Europaea Pollen Polymerized with Glutaraldehyde as a potential treatment for allergies, particularly those related to olive pollen. These studies aim to assess the efficacy and safety of this extract when administered as subcutaneous immunotherapy for patients suffering from moderate to severe allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma.

At a glance

Treatment
Allergenic Extract of Olea Europaea Pollen Polymerized with Glutaraldehyde
Administration Method
Subcutaneous injection
Target Condition
Moderate to severe allergic rhinitis/rhinoconjunctivitis due to olive pollen
Study Population
Adults aged 18-65 (some studies include patients as young as 12)
Primary Outcome Measure
Combined Symptom and Medication Score (CSMS) during peak pollen season
Secondary Outcomes
Quality of life, symptom-free days, immunological parameters, safety assessment
Study Design
Randomized, double-blind, placebo-controlled
Treatment Duration
Varies by study, typically several months to a year

What is Allergenic Extract of Olea Europaea Pollen Polymerized with Glutaraldehyde?

Allergenic Extract of Olea Europaea Pollen Polymerized with Glutaraldehyde is a medication used to treat allergies caused by olive tree pollen. It's also known by other names such as "Modified allergen extract of olive pollen polymerized with glutaraldehyde" or "T517". This medication is a type of allergen immunotherapy, which means it's designed to help your body become less sensitive to olive pollen over time.

How Does It Work?

This medication works by exposing your immune system to small, controlled amounts of olive pollen allergens. The allergens in this extract have been modified (or "polymerized") with a substance called glutaraldehyde. This modification helps to reduce the risk of severe allergic reactions while still allowing your immune system to build up tolerance to the allergen.

Over time, regular exposure to these modified allergens can help your immune system become less reactive to olive pollen. This can lead to a reduction in allergy symptoms when you're exposed to olive pollen in your environment.

What Conditions Does It Treat?

This medication is primarily used to treat moderate-to-severe allergic rhinitis or rhinoconjunctivitis caused by olive pollen. Let's break down these terms:

  • Allergic rhinitis: This is inflammation of the inside of the nose caused by an allergen, such as pollen. Symptoms can include sneezing, runny nose, and nasal congestion.
  • Rhinoconjunctivitis: This condition affects both the nose and the eyes. In addition to nasal symptoms, it can cause itchy, red, and watery eyes.

The medication can be used in patients with or without mild-to-moderate asthma, as long as the asthma is well-controlled.

How Is It Administered?

This medication is typically administered as a subcutaneous injection, which means it's injected just under the skin. The treatment usually follows a specific schedule:

  1. An initial phase where the dose is gradually increased
  2. A maintenance phase where you receive regular injections to maintain the effect

The exact dosing schedule can vary, but treatment may continue for several months or even years. It's important to follow your doctor's instructions carefully and attend all scheduled appointments.

Effectiveness

Clinical trials are currently underway to assess the effectiveness of this treatment. Researchers are looking at several measures to determine how well it works, including:

  • Reduction in allergy symptoms
  • Decreased need for allergy medications
  • Improvement in quality of life
  • Changes in immune system markers (like specific antibodies)

One of the main goals is to reduce what's called the "Combined Symptom and Medication Score" (CSMS) during the olive pollen season. This score takes into account both how severe a person's allergy symptoms are and how much medication they need to control those symptoms.

Safety and Side Effects

As with any medical treatment, there are potential side effects and safety considerations. Common side effects of allergen immunotherapy can include:

  • Reactions at the injection site (redness, swelling, itching)
  • Mild allergic reactions (such as increased allergy symptoms)

In rare cases, more severe allergic reactions can occur. That's why this treatment is always administered under medical supervision, and you'll be asked to stay at the clinic for a short time after each injection.

It's important to note that this treatment is not suitable for everyone. For example, it may not be recommended for people with severe or uncontrolled asthma, certain immune system disorders, or those taking specific medications.

Ongoing Research

Clinical trials are currently being conducted to further evaluate the effectiveness and safety of this treatment. These studies are looking at different doses of the medication and comparing it to a placebo (a treatment with no active ingredients).

Researchers are also studying how this treatment might be combined with other allergen extracts, such as grass pollen, for people who are allergic to multiple types of pollen.

As research continues, we may learn more about the best ways to use this treatment and who is most likely to benefit from it.

Questions people often ask

Conditions where Allergenic Extract Of Olea Europaea Pollen Polymerized With Glutaraldehyde is being studied

Each condition opens its own overview and trial list

Trials with Allergenic Extract Of Olea Europaea Pollen Polymerized With Glutaraldehyde

Recruiting trials first

See all 3 →
Quick filters
  • Participants:All ages
  • Participants:Adults
  • Participants:All ages
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).